MCLA-129 is under clinical development by Merus and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer. According to GlobalData, Phase II drugs for Paranasal Sinus And Nasal Cavity Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MCLA-129 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MCLA-129 overview
MCLA-129 is under development for the treatment of solid tumor including non-small cell lung cancer, gastric cancer, esophageal squamous cell cancer (ESCC), gastroesophageal junction (GC/GEJ) adenocarcinoma, Paranasal Sinus And Nasal Cavity Cancer; Oropharyngeal Cancer; Laryngeal Cancer, head and neck cancer and colorectal cancer. It is administered through intravenous drip. The therapeutic candidate is a bi-specific monoclonal antibody that acts by targeting epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (MET). The drug candidate is being developed based on Multiclonics (biclonics) technology platform.
Merus overview
Merus is a clinical-stage oncology company that develops innovative antibody therapeutics. The company utilizes the Multiclonics, Biclonics and Triclonics platforms to develop human bispecific and tri-specific antibodies. Its pipeline products include petosemtamab (MCLA-158), a low-fucose human full-length IgG1 antibody that targets head and neck squamous cell carcinoma (HNSCC); MCLA-129 and MCLA-145 targeting advanced non-small cell lung cancer (NSCLC) and solid tumors; Zenocutuzumab (MCLA-128), antibody-dependent cell-mediated cytotoxicity (ADCC) drug for non-small cell lung cancer and pancreatic cancer; ONO-4685 for refractory T cell lymphoma and psoriasis; and INCA32459 and INCA33890 for advanced malignancies and select advanced solid tumors. The company operates through its subsidiaries in the Netherlands and the US. Merus is headquartered in Utrecht, the Netherlands.
For a complete picture of MCLA-129’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
